127 related articles for article (PubMed ID: 37293958)
21. Presence of TERT ± BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma.
Lee J; Ha EJ; Roh J; Kim HK
Surgery; 2021 Sep; 170(3):743-747. PubMed ID: 33952391
[TBL] [Abstract][Full Text] [Related]
22. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
[TBL] [Abstract][Full Text] [Related]
23. Lack of BRAF(V600E) mutations in giant congenital melanocytic nevi in a Chinese population.
Wu D; Wang M; Wang X; Yin N; Song T; Li H; Yu J; Wang DM; Zhao Z
Am J Dermatopathol; 2011 Jun; 33(4):341-4. PubMed ID: 21430505
[TBL] [Abstract][Full Text] [Related]
24. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
[TBL] [Abstract][Full Text] [Related]
25. Effect of BRAF
Mu ZZ; Zhang YQ; Sun D; Lu T; Lin YS
Endocr Pract; 2022 Mar; 28(3):265-270. PubMed ID: 34890787
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic features and immunohistochemical spectrum of 11 cases of epithelioid malignant peripheral nerve sheath tumors, including INI1/SMARCB1 results and BRAF V600E analysis.
Rekhi B; Kosemehmetoglu K; Tezel GG; Dervisoglu S
APMIS; 2017 Aug; 125(8):679-689. PubMed ID: 28452074
[TBL] [Abstract][Full Text] [Related]
27. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma.
Pagès M; Beccaria K; Boddaert N; Saffroy R; Besnard A; Castel D; Fina F; Barets D; Barret E; Lacroix L; Bielle F; Andreiuolo F; Tauziède-Espariat A; Figarella-Branger D; Puget S; Grill J; Chrétien F; Varlet P
Brain Pathol; 2018 Jan; 28(1):103-111. PubMed ID: 27984673
[TBL] [Abstract][Full Text] [Related]
28. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
[TBL] [Abstract][Full Text] [Related]
29. BRAF
Wang W; Wang M; Jiang H; Wang T; Da R
BMC Neurol; 2021 May; 21(1):195. PubMed ID: 33980169
[TBL] [Abstract][Full Text] [Related]
30. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
[TBL] [Abstract][Full Text] [Related]
31. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
32. Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma.
Lim-Fat MJ; Song KW; Iorgulescu JB; Andersen BM; Forst DA; Jordan JT; Gerstner ER; Reardon DA; Wen PY; Arrillaga-Romany I
J Neurooncol; 2021 May; 152(3):515-522. PubMed ID: 33646525
[TBL] [Abstract][Full Text] [Related]
33. Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions.
Shimada Y; Tajima Y; Nagahashi M; Ichikawa H; Oyanagi H; Okuda S; Takabe K; Wakai T
J Surg Res; 2018 Dec; 232():72-81. PubMed ID: 30463788
[TBL] [Abstract][Full Text] [Related]
34. BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas.
Lee D; Cho YH; Kang SY; Yoon N; Sung CO; Suh YL
J Surg Oncol; 2015 Mar; 111(3):359-64. PubMed ID: 25346165
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapy for BRAFV600E malignant astrocytoma.
Nicolaides TP; Li H; Solomon DA; Hariono S; Hashizume R; Barkovich K; Baker SJ; Paugh BS; Jones C; Forshew T; Hindley GF; Hodgson JG; Kim JS; Rowitch DH; Weiss WA; Waldman TA; James CD
Clin Cancer Res; 2011 Dec; 17(24):7595-604. PubMed ID: 22038996
[TBL] [Abstract][Full Text] [Related]
36. BRAF mutations in metanephric adenoma of the kidney.
Choueiri TK; Cheville J; Palescandolo E; Fay AP; Kantoff PW; Atkins MB; McKenney JK; Brown V; Lampron ME; Zhou M; Hirsch MS; Signoretti S
Eur Urol; 2012 Nov; 62(5):917-22. PubMed ID: 22727996
[TBL] [Abstract][Full Text] [Related]
37. Expanding the Spectrum of
De Leo A; Serban D; Maloberti T; Sanza V; Coluccelli S; Altimari A; Gruppioni E; Chiarucci F; Corradini AG; Repaci A; Colapinto A; Nannini M; Pantaleo MA; de Biase D; Tallini G
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835466
[TBL] [Abstract][Full Text] [Related]
38. BRAF V600E Mutations Occur in a Subset of Glomus Tumors, and Are Associated With Malignant Histologic Characteristics.
Karamzadeh Dashti N; Bahrami A; Lee SJ; Jenkins SM; Rodriguez FJ; Folpe AL; Boland JM
Am J Surg Pathol; 2017 Nov; 41(11):1532-1541. PubMed ID: 28834810
[TBL] [Abstract][Full Text] [Related]
39. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
